Sirnaomics Initiates Phase I/II Trial for STP705 in Facial Squamous Cell Carcinoma
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced the first subject systemic dosing in...
HKG: 2257
Sirnaomics’ STP705 Receives Approval for Liver Cancer Trial in Taiwan
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced that it has received approval from...
Sirnaomics’ STP705 Shows Promising Results in Skin Cancer Trial
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced the peer-reviewed publication of Phase IIa...